Role of Anticoagulation in Lowering the Mortality in Hospitalized Covid-19 Patients: Meta-analysis of Available Literature

Overview

Journal Saudi Med J

Specialty General Medicine

Date 2022 Jun 8

PMID 35675936

Authors

Muhammad Aamir Waheed

Khalid Rashid

Tawfik Rajab

Ahmad Rajab

Adnan H Adnan

Harris Fayyaz

Ahmad A Ibad

Rabia Basri

Yahya Khan

Habib I Alhabib

Abdelnaser Elzouki

Affiliations

Soon will be listed here.

Abstract

Objectives: To reducing the risk of venous thromboembolic (VTE) events and subsequent mortality in covid-19 patients is still a matter of research. This systematic review and meta-analysis serve the purpose of comparing the mortality associated with the intensity of anticoagulation in patients admitted with covid-19.

Methods: A total of 7120 patients were recruited in 11 studies comparing using prophylactic anticoagulants against therapeutic anticoagulants.

Results: Our study showed that using prophylactic anticoagulants was associated with a 42% reduction in mortality compared to therapeutic anticoagulants (OR 0.58 (95% CI:0.676-0.499), =0.000). Also, we assessed mortality in patients using no anticoagulants against using prophylactic anticoagulants. A total of 6069 patients were recruited in 4 studies in which 2 studies significantly favored prophylactic anticoagulants in terms of reducing mortality. Cumulatively, the meta-analysis showed that using prophylactic anticoagulants was associated with a 5% reduction in mortality but without any statistical significance: (OR 1.049 [95% CI 1.237 - 0.865]) (=0.626).

Conclusion: Our meta-analysis favors using prophylactic anticoagulation in covid-19 patients reduces all-cause mortality in comparison to therapeutic anticoagulation however the impact on mortality when compared with no anticoagulation was not significant.PROSPERO Number: CRD42021257320.

Citing Articles

A Literature Review of Pathophysiology, Clinical Manifestations, Medications and Optimal Dosage, Outpatient, and Post-hospitalization Use of Anticoagulation in COVID-19 Patients.

Velissaris D, Michailides C, Karalis I, Paraskevas T, Koniari I, Pierrakos C Anatol J Cardiol. 2023; 27(5):232-239.

PMID: 37119193 PMC: 10160838. DOI: 10.14744/AnatolJCardiol.2023.3023.

References

Loo J, Spittle D, Newnham M . COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax. 2021; 76(4):412-420. DOI: 10.1136/thoraxjnl-2020-216243. View

Russo V, Di Maio M, Attena E, Silverio A, Scudiero F, Celentani D . Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study. Pharmacol Res. 2020; 159:104965. PMC: 7256617. DOI: 10.1016/j.phrs.2020.104965. View

Helms J, Severac F, Merdji H, Schenck M, Clere-Jehl R, Baldacini M . Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study. Ann Intensive Care. 2021; 11(1):14. PMC: 7829649. DOI: 10.1186/s13613-021-00809-5. View

Iba T, Levy J, Levi M, Thachil J . Coagulopathy in COVID-19. J Thromb Haemost. 2020; 18(9):2103-2109. PMC: 7323352. DOI: 10.1111/jth.14975. View

Zost S, Gilchuk P, Case J, Binshtein E, Chen R, Nkolola J . Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020; 584(7821):443-449. PMC: 7584396. DOI: 10.1038/s41586-020-2548-6. View

McGonagle D, Sharif K, ORegan A, Bridgewood C . The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020; 19(6):102537. PMC: 7195002. DOI: 10.1016/j.autrev.2020.102537. View

Ionescu F, Grasso-Knight G, Castillo E, Naeem E, Petrescu I, Imam Z . Therapeutic Anticoagulation Delays Death in COVID-19 Patients: Cross-Sectional Analysis of a Prospective Cohort. TH Open. 2020; 4(3):e263-e270. PMC: 7519875. DOI: 10.1055/s-0040-1716721. View

Motta J, Ogunnaike R, Shah R, Stroever S, Cedeno H, Thapa S . Clinical Outcomes With the Use of Prophylactic Versus Therapeutic Anticoagulation in Coronavirus Disease 2019. Crit Care Explor. 2020; 2(12):e0309. PMC: 7746209. DOI: 10.1097/CCE.0000000000000309. View

Atalla E, Zhang R, Shehadeh F, Mylona E, Tsikala-Vafea M, Kalagara S . Clinical Presentation, Course, and Risk Factors Associated with Mortality in a Severe Outbreak of COVID-19 in Rhode Island, USA, April-June 2020. Pathogens. 2020; 10(1). PMC: 7824344. DOI: 10.3390/pathogens10010008. View

10.

Schmitt F, Manolov V, Morgenstern J, Fleming T, Heitmeier S, Uhle F . Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care. 2019; 9(1):19. PMC: 6353981. DOI: 10.1186/s13613-019-0499-6. View

11.

Lu Y, Pan L, Zhang W, Cheng F, Hu S, Zhang X . A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19. Int J Infect Dis. 2020; 100:34-41. PMC: 7425668. DOI: 10.1016/j.ijid.2020.08.023. View

12.

Porfidia A, Valeriani E, Pola R, Porreca E, Rutjes A, Di Nisio M . Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thromb Res. 2020; 196:67-74. PMC: 7420982. DOI: 10.1016/j.thromres.2020.08.020. View

13.

Tremblay D, van Gerwen M, Alsen M, Thibaud S, Kessler A, Venugopal S . Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study. Blood. 2020; 136(1):144-147. PMC: 7332896. DOI: 10.1182/blood.2020006941. View

14.

Lawler P, Goligher E, Berger J, Neal M, McVerry B, Nicolau J . Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021; 385(9):790-802. PMC: 8362594. DOI: 10.1056/NEJMoa2105911. View

15.

Musoke N, Lo K, Albano J, Peterson E, Bhargav R, Gul F . Anticoagulation and bleeding risk in patients with COVID-19. Thromb Res. 2020; 196:227-230. PMC: 7444469. DOI: 10.1016/j.thromres.2020.08.035. View

16.

Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L . Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol. 2020; 189(3):428-437. PMC: 7262036. DOI: 10.1111/bjh.16659. View

17.

Hasan S, Radford S, Kow C, Zaidi S . Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis. J Thromb Thrombolysis. 2020; 50(4):814-821. PMC: 7396456. DOI: 10.1007/s11239-020-02235-z. View

18.

Han H, Ma Q, Li C, Liu R, Zhao L, Wang W . Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020; 9(1):1123-1130. PMC: 7473317. DOI: 10.1080/22221751.2020.1770129. View

19.

Mutlu G, Green D, Bellmeyer A, Baker C, Burgess Z, Rajamannan N . Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway. J Clin Invest. 2007; 117(10):2952-61. PMC: 1978421. DOI: 10.1172/JCI30639. View

20.

Poulakou G, Dimakakos E, Kollias A, Kyriakoulis K, Rapti V, Trontzas I . Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study. In Vivo. 2021; 35(1):653-661. PMC: 7880792. DOI: 10.21873/invivo.12305. View